Opendata, web and dolomites

GREEN LINE

A non-antibiotic treatment for Acne and Onychomycosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GREEN LINE project word cloud

Explore the words cloud of the GREEN LINE project. It provides you a very rough idea of what is the project "GREEN LINE" about.

fungi    containing    risk    nail    eighth    medical    life    viruses    commercialized    green    additional    quality    cosmetic    difficult    company    concentrate    onychomycosis    psycological    adults    destroy    bacteria    line    negative    complete    microbial    validation    market    acute    skin    international    sme    resistance    fungal    completion    roi    acne    10    mavena    innovative    class    ftes    worldwide    treatments    once    generating    uses    solution    adherence    respectively    solutions    population    territory    diseases    care    efficacy    approval    13    prescription    treatment    patients    health    thorugh    infection    clinical    instrument    antibiotics    global    efficiency    notfied    advantages    time    healthcare    peracids    prevalent    revenues    society    opens    90    reducing    48    teenagers    sold    markets    therapy    fourth    community    disease    boost    patient    mayor    limitations    65    notification    absence    medicinal    therapies    poor    physical    damage    reduces      

Project "GREEN LINE" data sheet

The following table provides information about the project.

Coordinator
MAVENA INTERNATIONAL AG 

Organization address
address: BOSCH 67
city: HUNENBERG
postcode: 6331
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://mavena.com/news-detail-417/mavena-international-ag-im-forschungs-und-innovationsprogramm-der-eu-horizon-2020.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAVENA INTERNATIONAL AG CH (HUNENBERG) coordinator 50˙000.00

Map

 Project objective

Acne and onychomycosis (nail fungal infection) are two of the most common skin diseases, affecting up to 90% of teenagers and 10% of adults, respectively. Acne is estimated to affect 9.4% of the global population, making it the eighth most prevalent disease worldwide. In addition to the health and cosmetic damage, there are psycological consequences for these patients, which have a great negative impact in quality of life. The current treatments for these diseases have limitations in terms of efficiency and side effects as well as containing antibiotics. As a result, there is poor patient adherence to these therapies contributing to increase the microbial resistance, a matter of great concern for global society. In response to this challenge, Mavena has developed innovative medical devices (Green Line) for the treatment of acne and onychomycosis. Green Line uses a novel concentrate of peracids which destroy bacteria, fungi and viruses thorugh a physical process. Green Line’s mayor advantages are its high efficacy compared to current solutions and the absence of antibiotics, improving therapy adherence and reducing the risk of microbial resistance. Green Line will be notfied as class III medical devices, and thus do not need such a long and difficult approval process as for a medicinal product. Moreover, after notification, Green Line medical devices can be sold within the whole European Community and do not require prescription. This reduces the time to the market and opens a large territory at once. Upon completion of the project, this solution will boost the growth of our company generating additional 13 FTEs, revenues of €65.1 M and a ROI of 7.48 by the fourth year after Phase 2 execution. With the help of the SME instrument, Mavena aims to complete the clinical validation of their product so that it can be commercialized across international markets, improving the quality of care of healthcare systems worldwide as well as the patient´s quality of life.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GREEN LINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GREEN LINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More